|
1
|
Lykidis A, Wang J, Karim MA and Jackowski
S: Overexpression of a mammalian ethanolamine-specific kinase
accelerates the CDP-ethanolamine pathway. J Biol Chem.
276:2174–2179. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Malito E, Sekulic N, Too WC, Konrad M and
Lavie A: Elucidation of human choline kinase crystal structures in
complex with the products ADP or phosphocholine. J Mol Biol.
364:136–151. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aoyama C, Ohtani A and Ishidate K:
Expression and characterization of the active molecular forms of
choline/ethanolamine kinase-alpha and -beta in mouse tissues,
including carbon tetrachloride-induced liver. Biochem J.
363:777–784. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gallego-Ortega D, Ramirez de Molina A,
Ramos MA, Valdes-Mora F, Barderas MG, Sarmentero-Estrada J and
Lacal JC: Differential role of human choline kinase alpha and beta
enzymes in lipid metabolism: Implications in cancer onset and
treatment. PLoS One. 4:e78192009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ramírez de Molina A, Gutiérrez R, Ramos
MA, Silva JM, Silva J, Bonilla F, Sánchez JJ and Lacal JC:
Increased choline kinase activity in human breast carcinomas:
Clinical evidence for a potential novel antitumor strategy.
Oncogene. 21:4317–4322. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nakagami K, Uchida T, Ohwada S, Koibuchi
Y, Suda Y, Sekine T and Morishita Y: Increased choline kinase
activity and elevated phosphocholine levels in human colon cancer.
Jpn J Cancer Res. 90:419–424. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ramírez de Molina A, Rodríguez-González A,
Gutiérrez R, Martínez-Piñeiro L, Sánchez J, Bonilla F, Rosell R and
Lacal J: Overexpression of choline kinase is a frequent feature in
human tumor-derived cell lines and in lung, prostate, and
colorectal human cancers. Biochem Biophys Res Commun. 296:580–583.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shah T, Wildes F, Penet MF, Winnard PT Jr,
Glunde K, Artemov D, Ackerstaff E, Gimi B, Kakkad S, Raman V and
Bhujwalla ZM: Choline kinase overexpression increases invasiveness
and drug resistance of human breast cancer cells. NMR Biomed.
23:633–642. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rodríguez-González A, Ramirez de Molina A,
Fernández F and Lacal JC: Choline kinase inhibition induces the
increase in ceramides resulting in a highly specific and selective
cytotoxic antitumoral strategy as a potential mechanism of action.
Oncogene. 23:8247–8259. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bañez-Coronel M, Ramírez de Molina A,
Rodríguez-González A, Sarmentero J, Ramos MA, García-Cabezas MA,
García-Oroz L and Lacal JC: Choline kinase alpha depletion
selectively kills tumoral cells. Curr Cancer Drug Targets.
8:709–719. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gruber J, See Too WC, Wong MT, Lavie A,
McSorley T and Konrad M: Balance of human choline kinase isoforms
is critical for cell cycle regulation: Implications for the
development of choline kinase-targeted cancer therapy. FEBS J.
279:1915–1928. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
MacKeigan JP, Murphy LO and Blenis J:
Sensitized RNAi screen of human kinases and phosphatases identifies
new regulators of apoptosis and chemoresistance. Nat Cell Biol.
7:591–600. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Almeida MI, Reis RM and Calin GA: MicroRNA
history: Discovery, recent applications, and next frontiers. Mutat
Res. 717:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vella MC and Slack FJ: C. elegans
microRNAs. WormBook. 1–9. 2005.PubMed/NCBI
|
|
17
|
Williams AH, Liu N, van Rooij E and Olson
EN: MicroRNA control of muscle development and disease. Curr Opin
Cell Biol. 21:461–469. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Broderick JA and Zamore PD: MicroRNA
therapeutics. Gene Ther. 18:1104–1110. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stenvang J, Petri A, Lindow M, Obad S and
Kauppinen S: Inhibition of microRNA function by antimiR
oligonucleotides. Silence. 3:12012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Conde J, Oliva N, Atilano M, Song HS and
Artzi N: Self-assembled RNA-triple-helix hydrogel scaffold for
microRNA modulation in the tumour microenvironment. Nat Mater.
15:353–363. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jansson MD and Lund AH: MicroRNA and
cancer. Mol Oncol. 6:590–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
López-Terrada D, Cheung SW, Finegold MJ
and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum
Pathol. 40:1512–1515. 2009. View Article : Google Scholar
|
|
24
|
Brennecke J, Stark A, Russell RB and Cohen
SM: Principles of microRNA-target recognition. PLoS Biol.
3:e852005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Grimson A, Farh KK, Johnston WK,
Garrett-Engele P, Lim LP and Bartel DP: MicroRNA targeting
specificity in mammals: Determinants beyond seed pairing. Mol Cell.
27:91–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chua SL, See Too WC, Khoo BY and Few LL:
UBC and YWHAZ as suitable reference genes for accurate
normalisation of gene expression using MCF7, HCT116 and HepG2 cell
lines. Cytotechnology. 63:645–654. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
McDowell EM and Trump BF: Histologic
fixatives suitable for diagnostic light and electron microscopy.
Arch Pathol Lab Med. 100:405–414. 1976.PubMed/NCBI
|
|
30
|
Bandres E, Agirre X, Ramirez N, Zarate R
and Garcia-Foncillas J: MicroRNAs as cancer players: Potential
clinical and biological effects. DNA Cell Biol. 26:273–282. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Peterson SM, Thompson JA, Ufkin ML,
Sathyanarayana P, Liaw L and Congdon CB: Common features of
microRNA target prediction tools. Front Genet. 5:232014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang RY, Weng KF, Huang YC and Chen CJ:
Elevated expression of circulating miR876-5p is a specific response
to severe EV71 infections. Sci Rep. 6:241492016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cook JR, MacIntyre DA, Samara E, Kim SH,
Singh N, Johnson MR, Bennett PR and Terzidou V: Exogenous oxytocin
modulates human myometrial microRNAs. Am J Obstet Gynecol.
213:65.e1–e9. 2015. View Article : Google Scholar
|
|
34
|
Saiselet M, Gacquer D, Spinette A, Craciun
L, Decaussin-Petrucci M, Andry G, Detours V and Maenhaut C: New
global analysis of the microRNA transcriptome of primary tumors and
lymph node metastases of papillary thyroid cancer. BMC Genomics.
16:8282015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu X, Gao Y, Lu Y, Zhang J, Li L and Yin
F: Downregulation of NEK11 is associated with drug resistance in
ovarian cancer. Int J Oncol. 45:1266–1274. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huang YH, Lin KH, Chen HC, Chang ML, Hsu
CW, Lai MW, Chen TC, Lee WC, Tseng YH and Yeh CT: Identification of
postoperative prognostic microRNA predictors in hepatocellular
carcinoma. PLoS One. 7:e371882012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sun XH, Geng XL, Zhang J and Zhang C:
miRNA-646 suppresses osteosarcoma cell metastasis by downregulating
fibroblast growth factor 2 (FGF2). Tumour Biol. 36:2127–2134. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Azam AT, Bahador R, Hesarikia H, Shakeri M
and Yeganeh A: Downregulation of microRNA-217 and microRNA-646 acts
as potential predictor biomarkers in progression, metastasis, and
unfavorable prognosis of human osteosarcoma. Tumour Biol.
37:5769–5773. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li Z, Wu G, Sher RB, Khavandgar Z,
Hermansson M, Cox GA, Doschak MR, Murshed M, Beier F and Vance DE:
Choline kinase beta is required for normal endochondral bone
formation. Biochim Biophys Acta. 1840:2112–2122. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bollin F, Dechavanne V and Chevalet L:
Design of experiment in CHO and HEK transient transfection
condition optimization. Protein Expr Purif. 78:61–68. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Borawski J, Lindeman A, Buxton F, Labow M
and Gaither LA: Optimization procedure for small interfering RNA
transfection in a 384-well format. J Biomol Screen. 12:546–559.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jin HY, Gonzalez-Martin A, Miletic AV, Lai
M, Knight S, Sabouri-Ghomi M, Head SR, Macauley MS, Rickert RC and
Xiao C: Transfection of microRNA mimics should be used with
caution. Front Genet. 6:3402015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hengstermann A, D'Silva MA, Kuballa P,
Butz K, Hoppe-Seyler F and Scheffner M: Growth suppression induced
by downregulation of E6-AP expression in human
papillomavirus-positive cancer cell lines depends on p53. J Virol.
79:9296–9300. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mukherji S, Ebert MS, Zheng GX, Tsang JS,
Sharp PA and van Oudenaarden A: MicroRNAs can generate thresholds
in target gene expression. Nat Genet. 43:854–859. 2011. View Article : Google Scholar : PubMed/NCBI
|
